Les Brown's public disclosure about prostate cancer

Les Brown, the motivational speaker and author, disclosed that he has prostate cancer, but he has not publicly shared a specific timeline of when he was diagnosed or how long he has had the condition. Brown has spoken about his diagnosis in interviews and on social media, framing it as part of his personal health journey rather than providing detailed medical information.

What is publicly known is that Brown has used his platform to raise awareness about prostate cancer screening and the importance of regular health checkups, particularly for Black men, who face higher rates of prostate cancer and are more likely to be diagnosed at advanced stages. His openness about the diagnosis reflects a broader effort to destigmatize cancer conversations among public figures.

Because Brown has not released an official statement with specific dates or medical details, much of what circulates online is incomplete or based on secondhand reporting. If you are looking for his most recent statements about his health, his official social media accounts and verified interviews are the most reliable sources.

Key Takeaways

  • Les Brown has publicly disclosed a prostate cancer diagnosis but has not shared specific details about when he was diagnosed or the stage of his condition.
  • Brown has used his diagnosis to encourage other men, especially Black men, to get regular prostate cancer screenings.
  • Prostate cancer screening typically involves a blood test called PSA (prostate-specific antigen) and sometimes a digital rectal exam.
  • Black men have higher rates of prostate cancer and are more likely to be diagnosed at later stages, making early screening especially important for this population.

Why prostate cancer screening matters for Black men

Black men in the United States face a significantly higher burden of prostate cancer compared to white men. They are diagnosed more often, tend to be diagnosed at younger ages, and are more likely to have advanced disease at the time of diagnosis. These disparities are linked to a combination of biological factors, healthcare access differences, and systemic inequities in the medical system.

Major health organizations, including the American Cancer Society and the American Urological Association, recommend that Black men discuss prostate cancer screening with their doctor starting at age 40, rather than age 50 as recommended for men of average risk. This earlier conversation gives Black men and their doctors a chance to weigh the benefits and risks of screening together and make an informed decision.

Regular screening can catch prostate cancer earlier, when treatment options are broader and outcomes tend to be better. This is one reason why public figures like Les Brown speaking openly about their diagnosis can matter—it normalizes the conversation and may encourage other men to have screening discussions with their doctors.

How prostate cancer is detected

Prostate cancer screening typically begins with one or both of two tests. The first is a blood test that measures PSA (prostate-specific antigen), a protein produced by the prostate. Higher PSA levels can signal prostate cancer, but they can also result from benign conditions like an enlarged prostate or a urinary tract infection, so a single high result does not mean cancer is present.

The second test is a digital rectal exam (DRE), in which a doctor inserts a gloved, lubricated finger into the rectum to feel the prostate for lumps or abnormalities. Some doctors perform this test routinely during screening; others do not. If either test shows something unusual, the next step is usually an ultrasound or a biopsy, in which a small sample of prostate tissue is removed and examined under a microscope.

A diagnosis of prostate cancer requires a biopsy result showing cancer cells. The biopsy also determines the Gleason score, which rates how aggressive the cancer appears under the microscope. This score, along with PSA level and imaging results, helps doctors determine the stage and risk level of the cancer and discuss treatment options with the patient.

Treatment options for prostate cancer

Prostate cancer treatment depends on the stage of the cancer, the Gleason score, the patient's age and overall health, and personal preferences about side effects and quality of life. For early-stage, slow-growing cancers, doctors may recommend active surveillance—regular monitoring with PSA tests and sometimes repeat biopsies—rather than immediate treatment. This approach avoids the side effects of surgery or radiation in men whose cancer may never cause serious harm.

For cancers that require treatment, options include surgery (removing the prostate), radiation therapy (using high-energy beams to kill cancer cells), hormone therapy (blocking testosterone, which fuels prostate cancer growth), and chemotherapy (using drugs to kill cancer cells). Some men receive a combination of these treatments. The choice depends on the cancer's characteristics and the patient's goals and tolerance for side effects.

Advanced prostate cancers that have spread beyond the prostate may be treated with hormone therapy, chemotherapy, immunotherapy, or targeted drugs designed to attack specific mutations in the cancer cells. Treatment plans are individualized, and doctors discuss the benefits and risks of each option with the patient before proceeding.

Living with a prostate cancer diagnosis

A prostate cancer diagnosis can affect physical health, emotional well-being, and quality of life. Many men experience anxiety or depression after diagnosis, and some face side effects from treatment such as urinary incontinence, erectile dysfunction, or bowel problems. Support from family, friends, mental health professionals, and support groups can help men adjust to the diagnosis and manage these challenges.

Some men find it helpful to connect with other prostate cancer survivors through in-person or online support groups. Organizations like the American Cancer Society, Us Too International, and the Prostate Cancer Foundation offer educational resources, support group directories, and peer mentoring programs. Speaking with a counselor or therapist who has experience with cancer patients can also help with the emotional side of the diagnosis.

Regular follow-up care is important after a prostate cancer diagnosis, whether the patient is undergoing active treatment, active surveillance, or has completed treatment. Follow-up appointments allow the doctor to monitor PSA levels, check for side effects, and catch any recurrence early. The frequency and type of follow-up depend on the treatment received and the individual's risk of recurrence.

Frequently Asked Questions

Is prostate cancer always fatal?

No. Many men with prostate cancer live for many years after diagnosis, especially if the cancer is caught early. Some prostate cancers grow slowly and may never cause serious harm. The five-year survival rate for prostate cancer in the United States is high, though outcomes vary depending on the stage at diagnosis and the individual's age and overall health.

Can prostate cancer be prevented?

There is no proven way to prevent prostate cancer, but some research suggests that maintaining a healthy diet, exercising regularly, and maintaining a healthy weight may lower risk. The most effective step is early detection through screening, which allows treatment to begin when the cancer is most treatable.

What is the difference between PSA screening and a prostate biopsy?

PSA screening is a blood test that measures a protein level; it is not a diagnosis. A biopsy is a procedure in which tissue is removed and examined under a microscope to confirm whether cancer is present. A high PSA result may lead to a biopsy, but many men with high PSA do not have cancer.

Do all men need prostate cancer screening?

Screening recommendations vary by age and risk. Men of average risk are typically advised to discuss screening with their doctor starting at age 50. Black men and men with a family history of prostate cancer should have this conversation starting at age 40. The decision to screen should be made together with a doctor after discussing benefits and risks.